Erudio Healtherudio.com
Clinical trial · no report yet · Phase 3
NCT03803553 trial: what clinicians have said so far
Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
- NCT03803553 ↗
- Active, not recruiting
- Massachusetts General Hospital
- Focused size, estimated: 1–150 verified statements
We haven't built an HCP commentary report on NCT03803553 yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on NCT03803553 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Indexed so far | |
|---|---|
| 3 posts on X |
The trial
ClinicalTrials.gov- Official title
- Early Identification and Treatment of Occult Metastatic Disease in Stage III Colon Cancer
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Metastatic Colon Cancer; Stage III Colon Cancer
- Interventions
- FOLFIRI Protocol; ACTIVE SURVEILLANCE; Nivolumab Protocol; Encorafenib/Binimetinib/Cetuximab Protocol; Trastuzumab + Pertuzumab
- Arms
- ctDNA-POSITIVE: FOLFIRI Protocol · Experimental
- ctDNA-POSITIVE: ACTIVE SURVEILLANCE · Active comparator
- ctDNA-NEGATIVE: ACTIVE SURVEILLANCE · Active comparator
- ctDNA-POSITIVE MSI-H: NIVOLUMAB · Experimental
- ctDNA-POSITIVE BRAF Mutant: ENCORAFENIB/BINIMETINIB/CETUXIMAB · Experimental
- 6 Months Additional Trastuzumab and Pertuzumab · Experimental
- Enrollment
- 400 (estimated)
- Primary outcomes
- Disease-free survival (DFS)
- Clearance rate of ctDNA
- Sponsor
- Massachusetts General Hospital with Stand Up To Cancer
- Start
- Apr 16, 2020
- Primary completion
- Dec 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03803553 · updated Sep 9, 2026